Phaseline

Targets › SQLE

SQLE (Squalene monooxygenase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Feb 2028.

Catalyzes the stereospecific oxidation of squalene to (S)-2,3-epoxysqualene, and is considered to be a rate-limiting enzyme in steroid biosynthesis. (UniProt, Q14534)

Open in Phaseline: the race on SQLE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Swiss Cancer InstituteTerbinafine
Squalene epoxidase (SQLE) inhibitor
SQLEPhase 2Recurrent Prostate CancerFeb 2028

Conditions

Recurrent Prostate Cancer (1)

Modalities

small molecule (1)

Companies

Swiss Cancer Institute (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.